{
  "id": 10526863,
  "title": "Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)",
  "url": "https://urgent.news/2026/09/28/teva-continues-biosimilar-momentum-with-u-s-fda-approval-of-degevmatm",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T20:01:17.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-continues-biosimilar-momentum-with-u-s-fda-approval-of-degevma-denosumab-adet-a-biosimilar-to-xgeva-denosumab"
  },
  "original_language": "en",
  "account": null,
  "summary": "DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy. FDA approval of […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}